Lobbying Activity Report

2301-10876

Organization: Novartis Pharmaceuticals Canada Inc.
Associated registration: 1739-2301-23
Lobbying Activity date: 2021-06-10
Arranged a meeting: No
Posted date: 2021-07-15

In-house lobbyists who participated in the lobbying activity: Collette Williams
Sophie Rochon
Senior Public Office Holders who were lobbied in this activity: Mitch Moneo, Assistant Deputy Minister
Pharmaceutical Laboratory Blood Services, Health
 
Subject Matter of the Lobbying Activity
Specific Topics of Lobbying Communications Intended Outcomes Associated Subject Matters
Request a meeting to provide an update on the expansion of CAR-T therapy in Canada and to get ADM Moneo's perspective on how Novartis can work together with the BC Ministry of Health to facilitate local administration of CAR-T treatment for BC citizens who require this therapy. Discuss the best path forward to enable and facilitate BC patients eligible for KYMRIAH® (tisagenlecleucel) to be treated in their home province.
Background: In September of 2018, KYMRIAH® (tisagenlecleucel),) became the first ever chimeric antigen receptor T cell (CAR-T) therapy approved by Health Canada, marking a significant step forward in cancer treatment. Footnote1
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
 Health Footnote1
 
Senior officer who filed this Lobbying Activity Report: Christian Macher
 
The above name is that of the most senior paid officer who is responsible for filing a Lobbying Activity Report for the organization (the Designated Filer), whether that person participated in this lobbying activity or not.
 
  1. Footnote1  Indicates new information that was added through a Lobbying Activity Report.
Date Modified: